We are live on ! Find out more
RAPP

Rapport Therapeutics
RAPP

55 hedge funds and large institutions have $582M invested in Rapport Therapeutics in 2024 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 10

57% more funds holding

Funds holding: 35 → 55 (+20)

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

3.29% more ownership

Funds ownership: 74.47% → 77.76% (+3.3%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

2% less capital invested

Capital invested by funds: $593M → $582M (-$11.6M)

Holders
55
Holders Change
+20
Holders Change %
+57.14%
% of All Funds
0.79%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
30
Increased
11
Reduced
7
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$26.8M
2
BlackRock
BlackRock
New York
+$12.4M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$10.8M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$9.39M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.34M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$8.14M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.73M
3
Millennium Management
Millennium Management
New York
-$2.72M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.26M
5
SVCM
Saturn V Capital Management
Texas
-$1.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$112M +$10.8M +503,117 +10%
AVM
2
Arch Venture Management
Illinois
$76.4M – – –
CAM
3
Cormorant Asset Management
Massachusetts
$60.2M +$13.7K +638 +0%
Capital International Investors
4
Capital International Investors
California
$53.3M -$43 -2 -0%
JJ
5
Johnson & Johnson
New Jersey
$51.2M – – –
SI
6
Sofinnova Investments
California
$40.9M +$946K +44,032 +2%
T. Rowe Price Investment Management
7
T. Rowe Price Investment Management
Maryland
$35.4M +$4.13M +191,960 +13%
Goldman Sachs
8
Goldman Sachs
New York
$25.5M +$26.8M +1,247,171 New
AllianceBernstein
9
AllianceBernstein
Tennessee
$22.3M -$41.6K -1,937 -0.2%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$21.5M -$6.73M -313,197 -23%
PA
11
Perceptive Advisors
New York
$15.3M – – –
BlackRock
12
BlackRock
New York
$11.8M +$12.4M +576,118 New
Vanguard Group
13
Vanguard Group
Pennsylvania
$10.4M +$9.39M +436,767 +624%
Citadel Advisors
14
Citadel Advisors
Florida
$9.48M -$2.26M -105,000 -18%
SL
15
Siren LLC
Connecticut
$7.87M +$8.26M +384,197 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$4.13M +$4.34M +201,748 New
LGM
17
Logos Global Management
California
$4.06M – – –
WP
18
Woodline Partners
California
$3.82M +$332K +15,460 +9%
EAM
19
Eventide Asset Management
Massachusetts
$2.26M +$1.3M +60,401 +121%
Manulife (Manufacturers Life Insurance)
20
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.58M +$39.3K +1,828 +2%
Charles Schwab
21
Charles Schwab
California
$1.5M +$1.57M +73,146 New
Northern Trust
22
Northern Trust
Illinois
$1.48M +$1.55M +72,212 New
Norges Bank
23
Norges Bank
Norway
$1.43M – – –
TD Asset Management
24
TD Asset Management
Ontario, Canada
$1.33M -$845K -39,324 -39%
State Street
25
State Street
Massachusetts
$1.19M +$1.25M +58,046 New
1
2 3

RAPP Hedge Fund Activity: Q3 2024 in Review

55 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q3 2024, worth a combined $582M — down 1.9% from $593M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new RAPP positions and 10 closed out — a net gain of 20 holders — while 11 added to existing stakes and 7 trimmed.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $26.8M. The largest seller was Artal Group, exiting entirely with an estimated $8.14M sold.

  • 55 institutional investors held Rapport Therapeutics (RAPP) as of Q3 2024, up from 35 in Q2 2024.
  • Funds reported $582M of Rapport Therapeutics stock for Q3 2024, down 1.9% quarter-over-quarter.
  • 30 funds opened new Rapport Therapeutics positions in Q3 2024 and 10 closed out, a net change of +20 holders.
  • The largest Rapport Therapeutics buyer in Q3 2024 was Goldman Sachs, an estimated $26.8M added.
  • The largest Rapport Therapeutics seller in Q3 2024 was Artal Group, an estimated $8.14M sold.

Based on aggregated 13F filings for Q3 2024.